Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (1933${count})

  • Research Grant, 2020
    RT-QuIC Assay for Alpha-synuclein in Incidental Lewy Body Disease

    Study Rationale:
    In Parkinson's, the alpha-synuclein protein misfolds and aggregates into clumps, called Lewy bodies. When Lewy bodies are found in people without Parkinson’s, it can be diagnosed as...

  • Research Grant, 2020
    Assessing Target Engagement for Terazosin

    Study Rationale:    
    Patients with Parkinson’s disease (PD) do not produce enough of a compound called ATP. If a person does not make enough ATP, the cells in the body can die. This is very important...

  • Research Grant Supplement, 2020
    LIMP-2 as a Scaffolding Protein to Characterize PD-Associated GCase Variants

    Promising Outcomes of Original Grant:
    Our original grant focused on determining the structure of the complex formed by the Parkinson’s-associated protein beta-gluccocerebrosidase (GCase) and its...

  • Therapeutic Pipeline Program, 2020
    Using Vestibular Stimulation to Improve Neurovascular Status in Parkinson’s Disease

    Study Rationale:    
    Caloric vestibular stimulation activates the vestibular system, a sensory network with pathways spreading throughout the brain. The vestibular system is responsible for providing...

  • Research Grant Supplement, 2020
    Measuring LRRK2-Mediated Rab Protein in Parkinson’s Disease

    Study Rationale: 
    The discovery of LRRK2 (Leucine rich repeat kinase 2) recently as a gene that causes Parkinson’s disease has provided considerable insights into the development of both familial and...

  • Research Grant Supplement, 2020
    Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein

    Study Rationale:    
    The development of alpha-synuclein and tau imaging agents will be valuable for people with Parkinson’s disease and Frontal Temporal Dementia (FTD), as deposits of these proteins...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.